Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 16/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963627 | 0.87 | TACR2 (0.43) | TACR2DGAT1LMNAACE | |
| SCHEMBL5970470 | 0.82 | TACR2 (0.45) | TACR2DGAT1 | |
| SCHEMBL5963174 | 0.81 | DGAT1 (0.43) | TACR2DGAT1LMNAACE | |
| SCHEMBL5963231 | 0.79 | MME (0.45) | TACR2DGAT1ACE | |
| SCHEMBL5963237 | 0.79 | MME (0.45) | TACR2DGAT1ACE | |
| SCHEMBL5963186 | 0.78 | CTSB (0.57) | DGAT1LMNAACE | |
| SCHEMBL5963480 | 0.74 | ECE1 (0.51) | TACR2ACE | |
| SCHEMBL5963484 | 0.74 | ECE1 (0.51) | TACR2ACE | |
| SCHEMBL5963655 | 0.73 | SMN1; SMN2 (0.48) | LMNAACEMEN1USP2KMT2A | |
| SCHEMBL5963487 | 0.71 | TACR2 (0.45) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430045-B1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | NOVARTIS AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | FINK CYNTHIA A | 2006-08-31 | — | — | US | disclosed |
| US-7071169-B2 | Pyrane derivatives as both ACE-and NEP-inhibitors | NOVARTIS AG (CH) | 2006-07-04 | — | — | US | disclosed |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | FINK CYNTHIA ANNE (US) | 2004-12-30 | — | — | US | disclosed |
| EP-1430045-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | Novartis AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027091-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS | NOVARTIS AG (CH) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | ECE1, ECE2, AGTR1 | TACR2 183/4885DGAT1 4395/4885LMNA 1277/4885 |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | ECE1, AGTR1, ACE | TACR2 622/4885DGAT1 3165/4885LMNA 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.